AstraZeneca Pharma India Limited (BOM: 506820)
India
· Delayed Price · Currency is INR 6,496.85
-9.00 (-0.14%)
At close: Dec 20, 2024
AstraZeneca Pharma India Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Net Income | 819.2 | 1,615 | 992.9 | 616 | 933 | 722.1 | Upgrade
|
| Depreciation & Amortization | 205.7 | 148.1 | 162.6 | 169.5 | 197.5 | 185.8 | Upgrade
|
| Other Amortization | 1.3 | 1.3 | - | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Assets | 1.6 | -0.3 | -24.9 | -28.2 | -21.7 | -2.9 | Upgrade
|
| Asset Writedown & Restructuring Costs | 12.4 | 12.4 | - | - | 3.8 | - | Upgrade
|
| Stock-Based Compensation | 43.5 | 27.4 | 23.7 | 18.2 | 14.8 | 11.2 | Upgrade
|
| Provision & Write-off of Bad Debts | 59.2 | 54.4 | 17 | 42.9 | 27.2 | 15.8 | Upgrade
|
| Other Operating Activities | -146.8 | -298 | -286.5 | -139.3 | -67.3 | -31.2 | Upgrade
|
| Change in Accounts Receivable | -260.7 | -511.8 | -231.7 | -49 | -45.8 | -48.3 | Upgrade
|
| Change in Inventory | -1,152 | -376.7 | -499.9 | 195.8 | 53.5 | -470.3 | Upgrade
|
| Change in Accounts Payable | 393.8 | -313.7 | 374.4 | 120.5 | -313.4 | 414.5 | Upgrade
|
| Change in Other Net Operating Assets | 191.5 | -79.5 | 55.3 | 61.6 | 266.2 | 77.5 | Upgrade
|
| Operating Cash Flow | 168.7 | 278.7 | 582.9 | 1,008 | 1,048 | 874.2 | Upgrade
|
| Operating Cash Flow Growth | -76.36% | -52.19% | -42.17% | -3.80% | 19.86% | 59.00% | Upgrade
|
| Capital Expenditures | -85.5 | -107.6 | -85.2 | -96.2 | -77.1 | -142.2 | Upgrade
|
| Sale of Property, Plant & Equipment | 2.2 | 4.1 | 34.8 | 32.5 | 24.2 | 4.9 | Upgrade
|
| Investment in Securities | - | - | - | - | 1,690 | -1,690 | Upgrade
|
| Other Investing Activities | 332.6 | 320.9 | 231.5 | 111.1 | 93.2 | 119.3 | Upgrade
|
| Investing Cash Flow | 249.3 | 217.4 | 181.1 | 47.4 | 1,730 | -1,708 | Upgrade
|
| Long-Term Debt Repaid | - | -38.6 | -38.5 | -35.1 | -28.8 | -22.1 | Upgrade
|
| Total Debt Repaid | -47.1 | -38.6 | -38.5 | -35.1 | -28.8 | -22.1 | Upgrade
|
| Net Debt Issued (Repaid) | -47.1 | -38.6 | -38.5 | -35.1 | -28.8 | -22.1 | Upgrade
|
| Common Dividends Paid | -600 | -400 | -200 | -50 | -50 | -25 | Upgrade
|
| Other Financing Activities | -6.9 | -5.2 | -6.3 | -9.5 | -10.9 | -16.5 | Upgrade
|
| Financing Cash Flow | -654 | -443.8 | -244.8 | -94.6 | -89.7 | -63.6 | Upgrade
|
| Net Cash Flow | -236 | 52.3 | 519.2 | 960.8 | 2,688 | -897.4 | Upgrade
|
| Free Cash Flow | 83.2 | 171.1 | 497.7 | 911.8 | 970.7 | 732 | Upgrade
|
| Free Cash Flow Growth | -86.98% | -65.62% | -45.42% | -6.07% | 32.61% | 101.71% | Upgrade
|
| Free Cash Flow Margin | 0.56% | 1.32% | 4.96% | 11.32% | 11.93% | 8.80% | Upgrade
|
| Free Cash Flow Per Share | 3.33 | 6.84 | 19.91 | 36.47 | 38.83 | 29.28 | Upgrade
|
| Cash Interest Paid | 6.9 | 5.2 | 6.3 | 9.5 | 10.9 | 11.4 | Upgrade
|
| Cash Income Tax Paid | 672.4 | 564.3 | 408.2 | 247.9 | 325.6 | 341.5 | Upgrade
|
| Levered Free Cash Flow | 34.33 | -37.96 | 762.44 | 901.26 | 841.91 | 762.48 | Upgrade
|
| Unlevered Free Cash Flow | 40.58 | -30.46 | 766.38 | 907.2 | 848.73 | 769.6 | Upgrade
|
| Change in Net Working Capital | 976.17 | 1,171 | 265.1 | -382.2 | 13.1 | -73.8 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.